Dexcom Inc (NASDAQ: DXCM) kicked off on Tuesday, up 1.71% from the previous trading day, before settling in for the closing price of $69.54. Over the past 52 weeks, DXCM has traded in a range of $54.11-$93.25.
During the last 5-year period, the sales growth of Healthcare Sector giant was 39.06%. While this was happening, its average annual earnings per share was recorded 25.61%. With a float of $384.35 million, this company’s outstanding shares have now reached $390.00 million.
Dexcom Inc (DXCM) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Dexcom Inc is 1.45%, while institutional ownership is 96.04%. The most recent insider transaction that took place on Nov 14 ’25, was worth 171,599. In this transaction Director of this company sold 2,906 shares at a rate of $59.05, taking the stock ownership to the 35,088 shares. Before that another transaction happened on Nov 14 ’25, when Company’s Director proposed sale 2,906 for $59.05, making the entire transaction worth $171,599.
Dexcom Inc (DXCM) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported 0.45 earnings per share (EPS), lower than consensus estimate (set at 0.5) by -0.05. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.47 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 25.61% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 22.02% during the next five years compared to 39.06% growth over the previous five years of trading.
Dexcom Inc (NASDAQ: DXCM) Trading Performance Indicators
Take a look at Dexcom Inc’s (DXCM) current performance indicators. Last quarter, stock had a quick ratio of 1.38. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.11. Likewise, its price to free cash flow for the trailing twelve months is 25.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.80, a number that is poised to hit 0.65 in the next quarter and is forecasted to reach 2.47 in one year’s time.
